Is cerebrolysin or semax better?

Semax, for almost everyone. It scores 7.1 against cerebrolysin's 6.3 and wins cognition (6.5 to 4.2), neuroplasticity (6.0 to 2.2) and nerve regeneration (4.5 to 2.0), at an ESTIMATED $12 to $60 a month. Cerebrolysin wins traumatic brain injury and elderly clinical populations, which is where its trials actually were.

Why does cerebrolysin score so low on general wellness uses?

Because it was never tested there. Its energy score is 1.8 and its stress-resilience score is 1.6, and both reflect an empty file rather than a failed trial. Every cerebrolysin trial is in acute stroke, brain injury or dementia. There is no cerebrolysin study showing anything in a healthy brain, so a low score is the honest reading.

Which one has better evidence for traumatic brain injury?

Cerebrolysin, and this is the closest call on the page, 4.3 against Semax's 4.5. CAPTAIN II randomized 142 patients with Glasgow Coma Scale 7 to 12 and found a significant multivariate benefit at day 90, with pooled effects of about 0.31 and 0.34 in Vester 2021. Semax's TBI relevance is inferred from overlapping mechanisms, with no dedicated trial.

How much does each one cost?

Both are ESTIMATES priced 2026-09-07. Semax is $12 to $60 a month, from a 30 mg 0.1% nasal spray at $40 to $100 covering 300 to 600 mcg a day. Cerebrolysin is $500 to $900 a month: 20 infusion days at 30 mL means 60 ampoules at roughly $8 to $14, plus clinic infusion fees on top.

Are they legal to buy in the US?

Neither is approved in the US, and both are gray market. Cerebrolysin is approved in parts of Europe and Asia, so buyers import genuine EVER Pharma product through overseas resellers. Semax is approved in Russia and sold here as a research nasal spray with no product standard. Athletes should treat both as anti-doping risky under the WADA S0 catch-all.

Semax, on the scores and on common sense. It rates 1.8 on safety risk and 1.8 on side effects against cerebrolysin's 2.0 and 2.3. The independent Cochrane stroke review found more non-fatal serious adverse events on cerebrolysin, and an unverified injectable biological carries sterility and cold-chain risk a nasal spray simply does not.

Can I use both together?

There is no reason to. Both converge on the same neurotrophic signaling, BDNF and NGF, so the combination is redundant rather than additive. You would be doubling gray-market sourcing risk and losing any ability to tell which one did something. Run one at a time against a marker you wrote down first.

How long before I know if either is working?

Semax gives a first change within about an hour, full effect around week 2, and a 2-week assessment window, so you find out fast and cheaply. Cerebrolysin takes about 7 days for a first change and 4 weeks to full effect, which is also the length of the studied infusion course. Judge at the end of the window, not during it.

Head-to-Head Comparison

Cerebrolysin vs Semax: Which Is Better for Brain Repair?

Should I use cerebrolysin or semax for brain repair?

Reviewed 09/07/2026

Semax scores 7.1 and cerebrolysin 6.3. Semax wins cognition, neuroplasticity and nerve regeneration, costs an ESTIMATED $12 to $60 a month, and goes up your nose. Cerebrolysin wins traumatic brain injury and geriatric use on real trials, but runs $500 to $900 a month through clinic infusions.

Semax wins on almost everything a functioning brain would want. Cerebrolysin wins where a brain is actually injured, which is the only place it was ever studied.
Cost decides more cases than efficacy here. An ESTIMATED $12 to $60 a month of nasal spray against $500 to $900 a month of imported ampoules plus clinic fees.
Cerebrolysin has the larger human trial base and the worse independent verdict. Cochrane found no benefit on death in stroke and more non-fatal serious adverse events.
Semax's human evidence is Russian, small and never independently replicated in the West. Its best mechanistic data, BDNF and TrkB upregulation, is in rats.
Both are gray market in the US, but not the same kind. Cerebrolysin is a real pharmaceutical you import. Semax is a research spray with no product standard.

At a Glance

Option A

Cerebrolysin

6.3 / 10 Worth trying

Upside

Efficacy 3.5
Breadth 3.8
Evidence 3.6
Speed 3.2
Durability 2.8
Bioindividuality 3.2

Downside

Safety Risk 2.0
Side Effects 2.3
Cost 3.0
Effort 4.0
Opportunity Cost 3.0
Dependency 1.8
Reversibility 1.6

Best at:

Neuroprotection 4.5
TBI 4.3
Cognition Focus 4.2
Memory 4.0

Porcine brain-derived peptide mixture given by IV or IM infusion. BioHarmony 6.3, worth trying.

Read full BioHarmony report →

Head-to-Head Verdict

Use Case	Winner	Rationale
TBI	Cerebrolysin	Cerebrolysin takes this despite the lower subrating, 4.3 against Semax's 4.5. This is the closest row in the matrix and the one where a real trial base decides it. CAPTAIN II (Muresanu 2020) randomized 142 patients with Glasgow Coma Scale 7 to 12 and found a significant multivariate benefit at day 90. Semax has no dedicated TBI trial at all.
Geriatric	Cerebrolysin	Cerebrolysin, again against the subratings, 2.5 to Semax's 5.0. It is the only one of the two ever randomized in an elderly clinical population: six Alzheimer's RCTs pooled in Gauthier 2015 and six vascular dementia RCTs in Cui 2019. The catch is large. The cognitive effect faded by six months and Cui rated the evidence very low quality. Neither supports healthy aging.
Cognition Focus	Semax	Semax, 6.5 against 4.2, and the two are not answering the same question. Cerebrolysin's cognition data is recovery-context only, a pooled Alzheimer's effect of about 0.40 at four weeks that lost significance by six months, in maker-funded trials. No cerebrolysin trial shows anything in a well brain. Semax has Russian attention and operative-memory work in healthy people.
Neuroplasticity	Semax	Semax by a wide margin, 6.0 against 2.2, though both scores are preclinical. Dolotov 2006 measured BDNF and TrkB upregulation in rat hippocampus after intranasal Semax with a conditioned-learning signal. Cerebrolysin's plasticity story is inference from review papers, per Al-Kuraishy 2025. No cerebrolysin trial ever used a plasticity marker as a registered outcome.
Nerve Regeneration	Semax	Semax, 4.5 against 2.0, and neither is strong. Russian optic-nerve use and preclinical neural-protection work make regrowth a plausible research direction for Semax. Cerebrolysin has no human regeneration endpoint at all: the recovery seen in its stroke and brain-injury trials is rehabilitation scoring, not demonstrated nerve tissue regrowth.
Memory	Tie	Honest tie, because the subratings and the evidence tier point opposite ways. Semax scores 6.0 but its memory data is animal work: Dolotov 2006 in rat hippocampus and Ellis 2020 in hypoxia-exposed rats. Cerebrolysin scores 4.0 on human memory-loaded dementia scales, which is a higher tier of evidence, undercut by maker funding, a fade by six months, and a very low quality rating.
Neuroprotection	Tie	Tie, and it is the most frustrating row here. Semax scores 6.5 on Gusev 2018, 110 post-stroke patients with BDNF and rehabilitation signals, unreplicated outside Russia. Cerebrolysin scores 4.5 on a much larger trial base its independent reviewer rejected: Ziganshina 2023 pooled seven stroke RCTs and 1,773 participants, found no benefit on death, and flagged more serious adverse events.
Injury Recovery	Tie	Neither, and the honest score is low on both: 2.5 for Semax and 2.0 for cerebrolysin. Neither has any tendon, ligament or muscle endpoint. Reading brain-injury recovery numbers as evidence for a sprained ankle is the exact mistake both reports warn against. If soft-tissue repair is the goal, this comparison is the wrong page.

Cost Comparison

Intervention	Monthly Cost	Notes
Cerebrolysin	$500 to $900	ESTIMATE, priced 2026-09-07, overseas pharmacy reseller channel. A 4-week dementia course is 20 infusion days at 30 mL, which is 60 ampoules of 10 mL, and resellers price those at roughly $8 to $14 each.Clinic infusion fees sit on top and are not in that range. Neither is travel, nor the time cost of 20 supervised sessions, which the report scores as the highest effort burden of the pair at 4.0.
Semax	$12 to $60	ESTIMATE, priced 2026-09-07, research-chemical channel. A pre-mixed 30 mg 0.1% nasal spray runs $40 to $100. At 300 mcg a day that is 9 mg a month, so $12 to $30. At 600 mcg a day it is 18 mg a month, so $24 to $60.There is no product standard behind that price, so concentration and storage are vendor-dependent. Cheap does not mean verified, and you are the one verifying.
The difference	Eight to seventy-five times more for cerebrolysin	$500 against $60 is more than eight times. $900 against $12 is seventy-five times. Both figures are estimates, so treat the shape of the gap rather than the decimal, and add clinic fees to the cerebrolysin side.That gap only earns itself in one situation: a diagnosed brain injury in the moderate-to-severe range, or a dementia workup where the trial population actually matches you. Outside that you are paying a clinical price for a non-clinical goal.

When to Switch

These run on very different clocks, so do not judge them the same way. Semax shows a first change within about an hour, full effect around week 2, and a 2-week assessment window. Cerebrolysin takes about 7 days for a first change, full effect around week 4, and a 4-week window that is also the length of the studied course.

Move from Semax to cerebrolysin only on a diagnosis, not a preference: moderate-to-severe traumatic brain injury with a Glasgow Coma Scale in the 7 to 12 range, severe ischemic stroke, or a dementia workup where a clinician is already involved. Those are the populations CAPTAIN II, CARS and the dementia meta-analyses actually enrolled, and all of them require supervised infusion, so the switch is a clinical decision rather than a purchase. Move from cerebrolysin to Semax when the goal turns out to be everyday cognition or focus rather than recovery, when a 4-week infusion course produced nothing measurable, or when the effort burden stops being worth it.

Do not run them together. Both act on the same neurotrophic signaling family, so the combination is redundant rather than additive, and stacking a gray-market injectable with a gray-market spray doubles the sourcing risk while confusing which one did anything. Either direction, keep one variable moving at a time and write down the marker before you start.

Who Should Pick What?

Adult recovering from a moderate-to-severe traumatic brain injury, working with a clinician

Cerebrolysin

This is the population CAPTAIN II enrolled, Glasgow Coma Scale 7 to 12, with a significant multivariate benefit at day 90 and pooled effects of about 0.31 and 0.34 at day 30 and day 90 in Vester 2021. Semax has no dedicated TBI trial. Know that the trials were maker-funded with company staff as co-authors.

Family evaluating options for a parent with vascular or Alzheimer's dementia

Cerebrolysin

Only cerebrolysin has been randomized in this population. Read the limitations before spending: the cognitive effect in Gauthier 2015 lost significance by six months, and Cui 2019 rated the vascular dementia evidence very low quality with every study industry-funded. Bring both reviews to the neurologist.

Experienced nootropic user wanting a focus experiment with a real mechanism

Semax

Cognition-focus 6.5 against 4.2, effect within about an hour, and a 2-week window so you find out fast. Cerebrolysin has never shown anything in a healthy brain and would cost you twenty clinic visits to find that out.

Older adult interested in neuroprotection without a diagnosis

Semax

Geriatric 5.0 against 2.5 for the undiagnosed case, and the practical argument is burden. A nasal spray at an ESTIMATED $12 to $60 a month is a reasonable tracked experiment. Twenty supervised infusions at $500 to $900 is not, without an indication that matches the trials.

Anyone who cannot verify what they are buying

Semax

If it comes down to which unverified product is safer to get wrong, it is the spray. A mislabeled nasal peptide is a wasted $40. A non-sterile injectable biological with a broken cold chain is an infection risk that exceeds the compound's own risk profile. That is why cerebrolysin's effort score is 4.0 and Semax's is 2.0.

Healthy adult hoping to speed up a torn hamstring or a post-surgical recovery

Tie

Neither. Injury-recovery scores are 2.5 and 2.0, and neither compound has a tendon, ligament or muscle endpoint anywhere in its record. Both reports say the same thing: the recovery data is central nervous system specific and does not transfer to soft tissue.

Research Highlights

Mechanism Difference
These two are redundant rather than complementary, because they converge on the same neurotrophic signaling. Cerebrolysin is a porcine brain-derived peptide mixture proposed to act like endogenous growth factors, targeting BDNF-like, GDNF-like and NGF-like signaling plus calpain and caspase-3.Semax reaches the same BDNF and NGF endpoints by a different door, through TrkB signaling, with cholinergic, melanocortin and enkephalin-degrading arms cerebrolysin does not have. Same destination, so stacking adds sourcing risk rather than mechanism.
Safety Comparison
Semax is the safer of the two on every axis the reports score: 1.8 on safety risk and 1.8 on side effects, against cerebrolysin's 2.0 and 2.3. The difference is route. A nasal spray cannot give you a bloodstream infection.Cerebrolysin's independent stroke review, Ziganshina 2023, found more non-fatal serious adverse events on the drug, and dizziness or vertigo is its most commonly reported effect. Semax's cautions are seizure history, high baseline anxiety and unstable psychiatric symptoms.
Access Risk
Both are gray market in the US, and they fail differently. Cerebrolysin is a genuine EVER Pharma product that Americans import through overseas resellers, so the risk is sterility, cold chain and counterfeiting on an injectable biological, which can exceed the compound's own risk.Semax is sold as a research nasal spray with no product standard, so purity, concentration and storage are vendor-dependent. One risks the route. The other risks the contents.
Cost Comparison
Both figures are ESTIMATES priced 2026-09-07. Cerebrolysin runs $500 to $900 a month: a 4-week course is 20 infusion days at 30 mL, so 60 ampoules at roughly $8 to $14 each, with clinic infusion fees on top of that.Semax runs $12 to $60 a month, from a 30 mg 0.1% nasal spray at $40 to $100 covering 300 to 600 mcg a day. That is a gap of eight to seventy-five times before anyone books a clinic chair.
Editorial Verdict
Semax scores 7.1 and cerebrolysin 6.3, and the gap understates how different they are. Semax wins cognition (6.5 to 4.2), neuroplasticity (6.0 to 2.2) and nerve regeneration (4.5 to 2.0), at a fraction of the cost and effort.Cerebrolysin wins the two rows where a diagnosis exists: traumatic brain injury and elderly clinical populations. Its low scores elsewhere reflect a narrow indication rather than a failure. It was never tested in a healthy brain, so it cannot claim one.

Frequently Asked Questions

Is cerebrolysin or semax better?: Semax, for almost everyone. It scores 7.1 against cerebrolysin's 6.3 and wins cognition (6.5 to 4.2), neuroplasticity (6.0 to 2.2) and nerve regeneration (4.5 to 2.0), at an ESTIMATED $12 to $60 a month. Cerebrolysin wins traumatic brain injury and elderly clinical populations, which is where its trials actually were.
Why does cerebrolysin score so low on general wellness uses?: Because it was never tested there. Its energy score is 1.8 and its stress-resilience score is 1.6, and both reflect an empty file rather than a failed trial. Every cerebrolysin trial is in acute stroke, brain injury or dementia. There is no cerebrolysin study showing anything in a healthy brain, so a low score is the honest reading.
Which one has better evidence for traumatic brain injury?: Cerebrolysin, and this is the closest call on the page, 4.3 against Semax's 4.5. CAPTAIN II randomized 142 patients with Glasgow Coma Scale 7 to 12 and found a significant multivariate benefit at day 90, with pooled effects of about 0.31 and 0.34 in Vester 2021. Semax's TBI relevance is inferred from overlapping mechanisms, with no dedicated trial.
How much does each one cost?: Both are ESTIMATES priced 2026-09-07. Semax is $12 to $60 a month, from a 30 mg 0.1% nasal spray at $40 to $100 covering 300 to 600 mcg a day. Cerebrolysin is $500 to $900 a month: 20 infusion days at 30 mL means 60 ampoules at roughly $8 to $14, plus clinic infusion fees on top.
Are they legal to buy in the US?: Neither is approved in the US, and both are gray market. Cerebrolysin is approved in parts of Europe and Asia, so buyers import genuine EVER Pharma product through overseas resellers. Semax is approved in Russia and sold here as a research nasal spray with no product standard. Athletes should treat both as anti-doping risky under the WADA S0 catch-all.
Which is safer?: Semax, on the scores and on common sense. It rates 1.8 on safety risk and 1.8 on side effects against cerebrolysin's 2.0 and 2.3. The independent Cochrane stroke review found more non-fatal serious adverse events on cerebrolysin, and an unverified injectable biological carries sterility and cold-chain risk a nasal spray simply does not.
Can I use both together?: There is no reason to. Both converge on the same neurotrophic signaling, BDNF and NGF, so the combination is redundant rather than additive. You would be doubling gray-market sourcing risk and losing any ability to tell which one did something. Run one at a time against a marker you wrote down first.
How long before I know if either is working?: Semax gives a first change within about an hour, full effect around week 2, and a 2-week assessment window, so you find out fast and cheaply. Cerebrolysin takes about 7 days for a first change and 4 weeks to full effect, which is also the length of the studied infusion course. Judge at the end of the window, not during it.

Evidence Sources

RCT CAPTAIN II single-center trial of cerebrolysin in moderate-to-severe traumatic brain injury, Neurological Sciences (2020) n=142, Glasgow Coma Scale 7 to 12; small-to-medium effect significant at day 90, safety comparable to placebo. EVER Pharma sponsor with company-staff conflict of interest.
Meta-analysis Pooled CAPTAIN brain-injury analysis, Neurological Sciences (2021) n=185; standardized mean difference about 0.31 at day 30 and 0.34 at day 90. First author is the sponsor-affiliated biometrician.
Systematic review Cerebrolysin for acute ischaemic stroke, Cochrane Database of Systematic Reviews (2023) 7 trials, 1,773 participants; no benefit on death (RR 0.96) and increased non-fatal serious adverse events. The key independent verdict against cerebrolysin.
Systematic review Cerebrolysin for vascular dementia, Cochrane Database of Systematic Reviews (2019) 6 trials, 597 participants; cognition standardized mean difference about 0.36 rated very low quality, all studies industry-funded.
Meta-analysis Cerebrolysin in Alzheimer's disease meta-analysis, Dementia and Geriatric Cognitive Disorders (2015) 6 RCTs; cognition standardized mean difference about 0.40 at 4 weeks, non-significant by 6 months. Sponsor-affiliated authors.
RCT CASTA acute ischemic stroke trial, Stroke (2012) n=1,070, the largest acute stroke trial of cerebrolysin; neutral on its primary global outcome at 90 days. 30 mL/day IV for 10 days.
RCT CARS rehabilitation trial of cerebrolysin plus physical therapy, Stroke (2016) 30 mL/day IV for 21 days plus standardized rehab; arm-recovery effect estimator about 0.71 at day 90. EVER Pharma staff among authors.
Meta-analysis Pooled CARS rehabilitation analysis, Neurological Sciences (2017) 442 patients; arm-recovery estimator about 0.62, number needed to treat about 7 for early benefit. Extensive sponsor disclosure.
Review Cerebrolysin dementia review naming dizziness or vertigo as the most common adverse event, Drugs and Aging (2009) Narrative review of dementia trials. Mechanism framing and the tolerability summary used for the safety comparison.
Review Possible role of cerebrolysin in the management of vascular dementia, Neuroscience (2025) Independent mechanistic review proposing blood-brain-barrier crossing and neurotrophic-like induction of neurogenesis and neuroplasticity. Mechanism, not measured human plasticity.
Preclinical Semax affects BDNF and TrkB expression in rat hippocampus, Brain Research (2006) BDNF and TrkB upregulation after intranasal Semax with a conditioned-learning signal. The anchor for the neuroplasticity and memory scores, in rats.
Trial Semax in combination with rehabilitation in post-ischemic stroke patients, Zh Nevrol Psikhiatr Im S S Korsakova (2018) 110 post-stroke patients; BDNF and rehabilitation outcome direction. Semax's strongest human signal, not independently replicated in the West.
Trial Nootropic analog of adrenocorticotropin 4-10 Semax, Zh Vyssh Nerv Deiat Im I P Pavlova (1997) Supports the attention and operative-memory direction in humans. Numbers not independently verified.
Trial Effects of Semax on human attention and memory, Neuroscience Research Communications (1996) Small human nootropic-like activity signal. Verified by DOI only, no PMID found.
Preclinical Protection of episodic memory by Semax in hypoxic-exposed rats, American Journal of Biomedical Science and Research (2020) Animal-only hypoxia and novel-object-recognition memory support. Part of why the Semax memory score is animal-weighted.
Preclinical Protective properties of Semax after cerebral ischemia-reperfusion in rats, Genes (2020) Preclinical transcriptomic support for the neuroprotection mechanism.
Preclinical Semax influences immune and vascular gene expression after focal cerebral ischemia, BMC Genomics (2014) Rat transcriptomic mechanism support for the post-ischemic response.
Authority WADA guidance on non-approved substances (S0) (2026) Explains the S0 non-approved substance category, which can apply to Semax even though it is not named directly.

Glossary

Quick reference for the medical and technical terms used in this comparison.

BDNF Brain-Derived Neurotrophic Factor: A protein that supports neuron survival, synaptic plasticity, learning and memory. Both compounds aim at it, by different routes.
TrkB Tropomyosin Receptor Kinase B: The main receptor for BDNF. Semax's plasticity case rests on TrkB upregulation measured in rat hippocampus.
NGF Nerve Growth Factor: A neurotrophin involved in neuron survival and repair. Both compounds are described as acting on NGF-like signaling.
ACTH Adrenocorticotropic Hormone: Semax is built from the ACTH 4-7 fragment plus a Pro-Gly-Pro tail for stability, not from the full hormone.
GCS Glasgow Coma Scale: A 3 to 15 score of consciousness after brain injury. CAPTAIN II enrolled patients scoring 7 to 12, which is the moderate-to-severe band.
SMD Standardized Mean Difference: A way to express effect size across different measurement scales. Cerebrolysin's effects cluster in the small-to-medium range, around 0.31 to 0.40.
Cochrane review Cochrane Systematic Review: An independent structured summary of all trials on a question, treated as a high bar for unbiased evidence. Both Cochrane reviews of cerebrolysin disagree with the maker's own trials.
SAE Serious Adverse Event: A trial event that is life-threatening, causes hospitalization or similar. The independent stroke review found more non-fatal ones on cerebrolysin than placebo.
Industry-funded Sponsor-Funded Trial: Paid for by the company selling the product, a known source of optimistic bias. Every positive cerebrolysin trial was industry-funded, several with company staff as co-authors.
WADA S0 Non-Approved Substances Category: The anti-doping catch-all covering pharmacological substances with no current regulatory approval. It can apply to a compound even when it is not named on the list.

Nick Urban Health Optimization Researcher & CHEK Holistic Lifestyle Coach Level 2

Semax was the first nootropic peptide I ever tried, potent enough that it convinced me to try a bunch of others

Reviewed Sep 7, 2026 · next review Dec 6, 2026

Find which one fits your biology

Take the BioHarmony Quiz